Anne-Marie Koop

3 97 57. Postic C, Leturque A, Printz RL, Maulard P, Loizeau M, Granner DK, Girard J. Development and regulation of glucose transporter and hexokinase expression in rat. Am J Physiol 1994;266:E548-59. 58. Frille A, Steinhoff KG, Hesse S, Grachtrup S, Wald A, Wirtz H, Sabri O, Seyfarth H-J. Thoracic [18F]fluorodeoxyglucose uptake measured by positron emission tomography/computed tomography in pulmonary hypertension. Med (United States) A. Frille, Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany; 2016;95. 59. Ohira H, deKemp R, Pena E, Davies RA, Stewart DJ, Chandy G, Contreras-Dominguez V, Dennie C, Mc Ardle B, Mc Klein R, Renaud JM, DaSilva JN, Pugliese C, Dunne R, Beanlands R, Mielniczuk LM. Shifts in myocardial fatty acid and glucose metabolism in pulmonary arterial hypertension: a potential mechanism for a maladaptive right ventricular response. Eur Heart J Cardiovasc Imaging England; 2015; 60. Sakao S, Daimon M, Voelkel NF, Miyauchi H, Jujo T, Sugiura T, Ishida K, Tanabe N, Kobayashi Y, Tatsumi K. Right ventricular sugars and fats in chronic thromboembolic pulmonary hypertension. Int J Cardiol S. Sakao, Department of Respirology (B2), Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan; 2016;219:143–149. 61. Bokhari S, Raina A, Rosenweig EB, Schulze PC, Bokhari J, Einstein AJ, Barst RJ, Johnson LL. PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging S. Bokhari, Department of Medicine, Division of Cardiology, NewYork Presbyterian Hospital at Columbia University Medical Center, New York, NY 10032, United States; 2011;4:641–647. 62. Saygin D, Highland KB, Farha S, Park M, Sharp J, Roach EC, Tang WHW, Thomas JD, Erzurum SC, Neumann DR, DiFilippo FP. Metabolic and functional evaluation of the heart and lungs in pulmonary hypertension by gated 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography. Pul m Circ 2017;7:428–438. 63. Nakaya T, Ohira H, Tsujino I. Right heart morphology, function and metabolism in pulmonary hypertension. Respir Cir c 2016;64:543–547. 64. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J, Takahashi T, Nawata J, Ido T, Watanabe J, Shirato K. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol Y. Kagaya, Department of Cardiovascular Medicine, Tohoku University, Graduate School of Medicine, Aoba-ku, Sendai 980-8574, Japan; 2005;45:1849–1855. 65. Lundgrin EL, Park MM, Sharp J, TangWHW, Thomas JD, Asosingh K, Comhair SA, DiFilippo FP, Neumann DR, Davis L, Graham BB, Tuder RM, Dostanic I, Erzurum SC. Fasting 2-deoxy- 2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc S.C. Erzurum, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, United States; 2013;10:1–9. 66. Li W, Wang L, Xiong C-M, Yang T, Zhang Y, Gu Q, Yang Y, Ni X-H, Liu Z-H, Fang W, He J-G. The Prognostic Value of 18F-FDG Uptake Ratio Between the Right and Left Ventricles in Idiopathic Pulmonary Arterial Hypertension. Clin Nucl Med 2015;40:859–863. 67. Tatebe S, Fukumoto Y, Oikawa-Wakayama M, Sugimura K, Satoh K, Miura Y, Aoki T, Nochioka K, Miura M, Yamamoto S, Tashiro M, Kagaya Y, Shimokawa H. Enhanced [18F] fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension: a preliminary observational study.